Living Indigenous Traditions
The use of psychedelic plants and fungi is not prehistory — it is living practice. Indigenous communities across the Americas, Africa, and elsewhere have maintained ceremonial relationships with psychedelic-producing organisms for generations. These are not primitive precursors to modern therapy; they are sophisticated, epistemologically coherent systems of knowledge and healing developed over centuries of careful practice.
The Mazatec people of Oaxaca, Mexico have used psilocybin mushrooms in healing ceremonies called veladas for generations — a practice still maintained by Mazatec healers (curanderas). The ayahuasca traditions of the Amazon basin — practiced by dozens of peoples including the Shipibo-Conibo, the Santo Daime, and the União do Vegetal — represent equally sophisticated bodies of ceremonial, ecological, and botanical knowledge. In North America, the peyote ceremony of the Native American Church has been practiced for over a century as a legally protected sacrament.
These traditions share common features that are absent from most contemporary Western psychedelic contexts: multi-generational transmission of knowledge, clearly defined ceremonial containers, community accountability, and integration of the experience within ongoing cosmological and ecological frameworks.
Indigenous psychedelic traditions belong to the peoples who developed them. Engagement by non-Indigenous people requires genuine relationship, humility, and reciprocity — not extraction of techniques or appropriation of ceremonial forms. The commercialisation of ayahuasca tourism and the decontextualised adoption of Indigenous practices in Western therapeutic settings are ongoing ethical concerns actively addressed by Indigenous researchers and communities.
The Western Encounter
The modern Western encounter with psychedelics began with the synthesis of LSD by Albert Hofmann at Sandoz Pharmaceuticals in 1938 — and its accidental self-administration in 1943, which Hofmann described in careful detail in his memoir LSD: My Problem Child. Hofmann also later participated in the isolation of psilocybin from Psilocybe mexicana in 1958, following a collaboration with R. Gordon Wasson.
Wasson's 1957 Life magazine article — "Seeking the Magic Mushroom" — is the inflection point at which Western public awareness of psilocybin mushrooms began. Wasson participated in a Mazatec ceremony led by María Sabina, whose subsequent exposure to international attention had profoundly negative consequences for her and her community — a cautionary history of well-intentioned but extractive Western engagement with Indigenous practice.
The 1960s and the Countercultural Moment
LSD entered psychiatric research in the 1950s and produced genuinely promising results — particularly for treatment of alcohol use disorder (research led by Humphry Osmond, Abram Hoffer, and colleagues) and end-of-life distress — work that attracted the passionate interest of Bill Wilson, co-founder of Alcoholics Anonymous, who credited LSD experiences with helping him overcome his own alcoholism and actively advocated for its therapeutic use within AA — though he was not a clinical researcher. But the research was overwhelmed by a cultural avalanche. Timothy Leary and Richard Alpert (later Ram Dass) at Harvard became the public faces of an experimental psychedelic culture that rapidly expanded beyond academic settings.
The counterculture of the 1960s used psychedelics as tools of social and political critique, consciousness expansion, and rebellion against the values of post-war consumer society. By the late 1960s, psychedelics had become deeply entangled with anti-war protest, civil rights, and an emerging ecological consciousness — associations that made them politically threatening to the Nixon administration.
Prohibition and Its Legacy
LSD was made illegal in the United States in 1968. Psilocybin, mescaline, and other psychedelics were placed in Schedule I — the most restrictive category — under the Controlled Substances Act of 1970. Similar restrictions followed internationally under the United Nations Convention on Psychotropic Substances (1971). Research effectively halted for three decades.
The political nature of this prohibition was acknowledged decades later by John Ehrlichman, Nixon's domestic policy advisor, who stated in a 2016 interview that the War on Drugs was "designed to associate the antiwar left and Black people with... LSD." The scheduling of psychedelics was a political act masquerading as a pharmacological one — a history with ongoing consequences for research, access, and the communities most harmed by drug enforcement.
The Psychedelic Renaissance
The contemporary psychedelic renaissance — the wave of clinical research, policy reform, and commercial development that began around 2000 and accelerated dramatically through the 2010s and early 2020s — represents a genuine scientific revival but also an uneven and sometimes troubling cultural moment.
The scientific revival is real: Johns Hopkins, Imperial College London, NYU, and others have produced rigorous clinical trial data on psilocybin, MDMA, ketamine, and LSD for depression, PTSD, addiction, and end-of-life distress. The quality of this research is markedly better than the 1960s work it follows.
Alongside this, a psychedelic industry has emerged: publicly traded pharmaceutical companies, venture-backed startups, retreat centres charging thousands of dollars per ceremony, and a therapeutic infrastructure that has reproduced many of the extractive logics of the healthcare system it claims to offer an alternative to.
Tensions at the Frontier
Commercialisation. Scholar Neşe Devenot and others have analysed "psychedelic capitalism" — the appropriation of countercultural and Indigenous frameworks to market commodified healing experiences. The concern is not that commercialisation exists but that it may reproduce extractive logics at scale, prioritising returns for investors over access for those most in need.
Epistemic extraction. The adoption of Indigenous ceremonial frameworks, plant medicines, and healing concepts in Western therapeutic contexts — without reciprocal relationship, attribution, or benefit-sharing with the communities who developed them — is a form of epistemic extraction. Researchers Yuria Celidwen, Nicole Redvers, and others have articulated detailed frameworks for ethical engagement.
Medicalisation. The biomedical framing of psychedelic therapy — necessary for clinical research — risks evacuating the relational, ecological, and spiritual dimensions of psychedelic experience that may be essential to its most significant effects.
Canadian Context
Canada has emerged as one of the more progressive jurisdictions in the world for psychedelic policy. Health Canada's Special Access Program and Section 56 exemptions have allowed a growing number of Canadians to access psilocybin-assisted therapy. Several provinces have active harm reduction and decriminalisation initiatives, and Indigenous-led organisations are working to establish frameworks for culturally grounded psychedelic practice that centre community sovereignty and traditional knowledge.